Comparative Pharmacology
Head-to-head clinical analysis: AEROLATE III versus BRONKODYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AEROLATE III versus BRONKODYL.
AEROLATE III vs BRONKODYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular cAMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.
Bronkodyl contains theophylline, a xanthine derivative. It acts as a bronchodilator by inhibiting phosphodiesterase, increasing cyclic AMP levels, leading to relaxation of bronchial smooth muscle. Additionally, it blocks adenosine receptors and may have anti-inflammatory effects.
Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.
Theophylline extended-release: 300-600 mg orally every 12 hours; target serum concentration 5-15 mcg/mL.
None Documented
None Documented
Terminal half-life 12-15 hours; clinically allows twice-daily dosing
Terminal elimination half-life is 3–8 hours in non-smoking adults, 1–5 hours in smokers, and 20–30 hours in premature neonates; clinical context: half-life increases in hepatic impairment, heart failure, and with certain medications (e.g., cimetidine, fluoroquinolones).
Renal: 60% unchanged; biliary/fecal: 30% as metabolites; 10% other
Renal: approximately 90% as theophylline and its metabolites (1,3-dimethyluric acid, 3-methylxanthine, 1-methyluric acid); biliary/fecal: <10%.
Category C
Category C
Bronchodilator
Bronchodilator